Pegozafermin

培泽夫明

Report date: 2026/05/08 09:39:27

Base Information

Drug NamePegozafermin
Drug Alias NameBIO89-100TEV-47948
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionFibroblast growth factor 21 agonists
TargetsFibroblast growth factor 21
Therapy Area/IndicationsHypertriglyceridemiaLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTeva Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active Companies89Bio Ltd89bio Inc
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG